Mechanistically, while the mechanism of action of mogamulizumab targeting CCR4 can effectively reduce the malignant T‐cell burden and promote antitumor immunity by depleting Treg cells in the tumor microenvironment, it also leads to hyperactivation of the Th1 immune response. This evidence concerns the gene CCR4 and neoplasm.